advertisement
11.14 Investigational drugs; pharmacological experiments (74)
Showing records 1 to 25
Display all abstracts in classification 11.14 Investigational drugs; pharmacological experiments
Search within classification 11.14 Investigational drugs; pharmacological experiments72728 Efficacy of Ripasudil as a Second-line Medication in Addition to a Prostaglandin Analog in Patients with Exfoliation Glaucoma: A Pilot Study
Matsumura R
Clinical Drug Investigation 2017; 37: 535-539
72682 Grooved Glaucoma Drainage Devices That Continuously Deliver Cyclosporine A Decrease Postsurgical Scar Formation in Rabbit Eyes
Dai Z
Investigative Ophthalmology and Visual Science 2017; 58: 1692-1701
72716 Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients
Haug NA
Addictive behaviors 2017; 72: 14-20
72679 Toll-like receptor 4 inhibitor protects against retinal ganglion cell damage induced by optic nerve crush in mice
Nakano Y
Journal of Pharmacological Sciences 2017; 133: 176-183
72828 Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability
Adelli GR
Investigative Ophthalmology and Visual Science 2017; 58: 2167-2179
72791 Quantification of the efficacy of collagen cross-linking agents to induce stiffening of rat sclera
Campbell IC
Journal of the Royal Society, Interface / the Royal Society 2017; 14:
72668 Peeking into Sigma-1 Receptor Functions Through the Retina
Mavlyutov TA
Adv Exp Med Biol 2017; 964: 285-297
73280 Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Lin CW
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 40-51
72730 Targeting Schlemm's Canal in the Medical Therapy of Glaucoma: Current and Future Considerations
Andrés-Guerrero V
Advances in Therapy 2017; 34: 1049-1069
73001 Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: For efficient intra ocular pressure reduction
Natesan S
International Journal of Biological Macromolecules 2017; 104: 1837-1845
72748 Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma
Lu LJ
The Yale journal of biology and medicine 2017; 90: 111-118
72713 An introduction to DARC technology
Ahmad SS
Saudi Journal of Ophthalmology 2017; 31: 38-41
72755 Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis
Yu-Wai-Man C
Scientific reports 2017; 7: 518
72669 The Role of Sigma 1 Receptor as a Neuroprotective Target in Glaucoma
Mysona B
Adv Exp Med Biol 2017; 964: 299-307
72828 Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability
Bhagav P
Investigative Ophthalmology and Visual Science 2017; 58: 2167-2179
73280 Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Sherman B
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 40-51
72730 Targeting Schlemm's Canal in the Medical Therapy of Glaucoma: Current and Future Considerations
García-Feijoo J
Advances in Therapy 2017; 34: 1049-1069
72682 Grooved Glaucoma Drainage Devices That Continuously Deliver Cyclosporine A Decrease Postsurgical Scar Formation in Rabbit Eyes
Yu X
Investigative Ophthalmology and Visual Science 2017; 58: 1692-1701
73001 Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: For efficient intra ocular pressure reduction
Pandian S
International Journal of Biological Macromolecules 2017; 104: 1837-1845
72668 Peeking into Sigma-1 Receptor Functions Through the Retina
Guo LW
Adv Exp Med Biol 2017; 964: 285-297
72669 The Role of Sigma 1 Receptor as a Neuroprotective Target in Glaucoma
Kansara N
Adv Exp Med Biol 2017; 964: 299-307
72679 Toll-like receptor 4 inhibitor protects against retinal ganglion cell damage induced by optic nerve crush in mice
Shimazawa M
Journal of Pharmacological Sciences 2017; 133: 176-183
72728 Efficacy of Ripasudil as a Second-line Medication in Addition to a Prostaglandin Analog in Patients with Exfoliation Glaucoma: A Pilot Study
Inoue T
Clinical Drug Investigation 2017; 37: 535-539
72748 Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma
Tsai JC
The Yale journal of biology and medicine 2017; 90: 111-118
72791 Quantification of the efficacy of collagen cross-linking agents to induce stiffening of rat sclera
Hannon BG
Journal of the Royal Society, Interface / the Royal Society 2017; 14:
